Nyxoah (NASDAQ:NYXH – Get Free Report) and Omnicell (NASDAQ:OMCL – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, profitability, risk, institutional ownership and valuation.
Volatility and Risk
Nyxoah has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.
Earnings and Valuation
This table compares Nyxoah and Omnicell”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nyxoah | $5.64 million | 18.60 | -$64.10 million | ($2.68) | -1.15 |
| Omnicell | $1.18 billion | 1.27 | $2.05 million | $0.04 | 827.25 |
Omnicell has higher revenue and earnings than Nyxoah. Nyxoah is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
97.7% of Omnicell shares are held by institutional investors. 17.1% of Nyxoah shares are held by company insiders. Comparatively, 2.5% of Omnicell shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Nyxoah and Omnicell’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nyxoah | -884.69% | -128.85% | -80.78% |
| Omnicell | 0.17% | 3.00% | 1.81% |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Nyxoah and Omnicell, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nyxoah | 1 | 0 | 3 | 1 | 2.80 |
| Omnicell | 1 | 1 | 6 | 0 | 2.63 |
Nyxoah currently has a consensus target price of $11.33, indicating a potential upside of 267.97%. Omnicell has a consensus target price of $58.50, indicating a potential upside of 76.79%. Given Nyxoah’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Nyxoah is more favorable than Omnicell.
Summary
Omnicell beats Nyxoah on 9 of the 15 factors compared between the two stocks.
About Nyxoah
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
About Omnicell
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.
